Brigham Young University revealed on Thursday that its FDA listed alcohol-free Disinfect & Shield hand sanitizer containing benzalkonium chloride are just as effective against the COVID-19 virus as alcohol-based products based on a new research based study.
The new study was reportedly published in The Journal of Hospital Infection.
According to the university , the Disinfect & Shield Hand Sanitizer is available as a moisture-infused foam or spray that leaves an invisible, breathable barrier on the skin. It not only destroys 99.99% of bacteria but is also eco-friendly, making it ultra-safe for use around pets and plants while protecting the treated area for up to a full eight hours. The product is effective against numerous viruses, bacteria, moulds, and fungi enveloped and non- enveloped, including strains of SARS, MRSA and Staph infection.
Disinfect & Shield is a fast-acting nanotechnology that destroys viruses and bacteria and prevents them from attaching to skin, surfaces, and clothes. The colourless, odourless, positively charged polymer bonds to the treated surface creating a layer of electrically charged swords. They protect the surface from biofilm growth by puncturing the cell membrane. It is alcohol-free and eliminates the harsh fumes and cracked, dry skin that accompanies alcohol-based sanitizers and its safe for use on PPE like gloves, concluded the university.
Viking Therapeutics plans offerings of common stock and convertible senior notes
Astellas doses first patient in Phase 3 lung cancer study
AstraZeneca's Trixeo Aerosphere approved in EU for asthma maintenance treatment
Ondine Biomedical deployssteriwave across five Southern Ontario hospitals
Ionis reports positive Phase 3 sefaxersen data in IgA nephropathy
X-Chem and Relay Therapeutics collaborate on Phase 3 milestone
BoomRay enters exclusive radioligand therapy asset global license agreement with Novartis
AstronauTx receives funding to explore sleep-based approaches for Parkinson's disease
AbbVie secures EU approval for RINVOQ in polyarticular juvenile idiopathic arthritis
Genentech reports positive Phase II results for enicepatide in type 2 diabetes
Pharming reports positive Phase II data for leniolisib in primary immunodeficiencies
Insmed's ARIKAYCE sNDA granted priority review by FDA
Precigen announces FDA platform technology designation for AdenoVerse
Enhertu recommended for EU approval in early HER2-positive breast cancer
PureTech receives FDA Fast Track designation for LYT-200 in HR-MDS